CareLit · DOI-Nachweis · Zeitschrift für Gastroenterologie
Early efficacy and safety of adalimumab therapy in patients with Crohn's disease
DOI 10.1055/s-0029-1223990
Bibliografische Angaben
Nachweis in CareLit
Autor:innenZ Czegledi, P Miheller, T Szamosi, J Banai, Z Tulassay, O Gemela, J Papp, P Lakatos
ZeitschriftZeitschrift für Gastroenterologie
Ausgabe05/2009
Jahrgang / SeitenNicht angegeben
Kernaussage aus der Literatur
Abstract-Vorschau
Aims: Adalimumab is a fully human monoclonal antibody targeting tumor necrosis factor. We assess the early efficacy and frequency of side effects during induction and maintenance adalimumab therapy in patients with Crohn's disease. Methods: 54 CD patients were analyzed. (male/female: 34/20, mean age: 31.3 years, duration: 8.7 years). Indication for biologic therapy was steroid dependency and/or steroid refractory di…
Zitieren
Zitierempfehlung
Z Czegledi, P Miheller, T Szamosi, J Banai, Z Tulassay, O Gemela, J Papp, P Lakatos (2009) Early efficacy and safety of adalimumab therapy in patients with Crohn's disease. Zeitschrift für Gastroenterologie (05). https://doi.org/10.1055/s-0029-1223990
Mit CareLit weiterarbeiten